Pilot Trial of LET Optimized IMPT for Pediatric Patients With Ependymoma
Who is this study for? Patients with Ependymoma
What treatments are being studied? Linear Energy Transfer-Optimized Intensity Modulated Proton Therapy+Quality-of-Life Assessment+Questionnaire Administration
Status: Recruiting
Location: See all (2) locations...
Intervention Type: Other, Radiation
Study Type: Interventional
Study Phase: Phase 1
SUMMARY
This phase I trial studies the side effects of linear energy transfer (LET) optimized image modulated proton therapy (IMPT) in treating pediatric patients with ependymoma. Radiation therapy such as LET optimized IMPT, uses proton beams to kill tumor cells and shrink tumors without damaging surrounding normal tissues.
Eligibility
Participation Requirements
Sex: All
Maximum Age: 22
Healthy Volunteers: f
View:
• Previous pathologic confirmation of ependymoma, World Health Organization (WHO) grade II or III
• Disease must be confined to the brain (no evidence of spread on MR imaging of the spine or on staging lumbar puncture)
• Patient may not receive chemotherapy concurrent with radiation
• Signed informed consent by patient and/or parents or legal guardian
• Lansky performance status score of 50 -100
Locations
United States
Massachusetts
Massachusetts General Hospital Cancer Center
NOT_YET_RECRUITING
Boston
Texas
M D Anderson Cancer Center
RECRUITING
Houston
Contact Information
Primary
David Grosshans
dgrossha@mdanderson.org
713-563-2300
Time Frame
Start Date: 2019-04-01
Estimated Completion Date: 2027-12-31
Participants
Target number of participants: 48
Treatments
Experimental: Treatment (LET optimized IMPT)
Patients receive LET optimized IMPT for up to 6 weeks.
Authors
Related Therapeutic Areas
Sponsors
Leads: M.D. Anderson Cancer Center
Collaborators: National Cancer Institute (NCI)